Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURIGAST: FOLFIRI + Durvalumab +/- Tremelimumab in Gastric Cancer
NCT03959293Phase 2Active, not recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2019
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Started Jul 2019; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03959293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959293.